Business

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY. A live webcast of the presentation can be accessed through th

Akebia Therapeutics, Inc.May 28, 20261
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

About this update from Akebia Therapeutics, Inc.

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY. A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at  https://ir.akebia.com . A replay of the webcast will also be available for 90 days following the presentation. The 2026 Jefferies Global Healthcare Conference will take place June 2-4, 2026, in New York, NY. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at  www.akebia.com , which does not form a part of this release. Akebia Therapeutics Contact Mercedes Carrasco [email protected]

View stock analysis, news, and events for Akebia Therapeutics, Inc.

biopharmaceutical companyAkebia TherapeuticsJefferies Global Healthcare Conferencekidney diseaseAkebia Therapeutics, Inc.Nicholas Grund

More from Akebia Therapeutics, Inc.

All Akebia Therapeutics, Inc. news →